EA201001781A1 - Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов - Google Patents

Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов

Info

Publication number
EA201001781A1
EA201001781A1 EA201001781A EA201001781A EA201001781A1 EA 201001781 A1 EA201001781 A1 EA 201001781A1 EA 201001781 A EA201001781 A EA 201001781A EA 201001781 A EA201001781 A EA 201001781A EA 201001781 A1 EA201001781 A1 EA 201001781A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycosaminoglycans
oral administration
composition
gastrointestinal tract
upper gastrointestinal
Prior art date
Application number
EA201001781A
Other languages
English (en)
Other versions
EA018333B1 (ru
Inventor
Анджело Пиццони
Original Assignee
П4П Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by П4П Интернэшнл Лимитед filed Critical П4П Интернэшнл Лимитед
Publication of EA201001781A1 publication Critical patent/EA201001781A1/ru
Publication of EA018333B1 publication Critical patent/EA018333B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к применению ассоциата гликозаминогликанов гиалуроновой кислоты и хондроитинсульфата для получения вводимых перорально композиций для профилактики или лечения заболеваний верхней части желудочно-кишечного тракта и лекарственных средств для лечения повреждений эпителия верхней части желудочно-кишечного тракта, а также композициям для перорального введения, содержащих указанную ассоциацию гликозаминогликанов.
EA201001781A 2008-05-13 2009-05-08 Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов EA018333B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008001181 2008-05-13
PCT/IB2009/005549 WO2009138843A1 (en) 2008-05-13 2009-05-08 Glycosaminoglycan oral use and compositions

Publications (2)

Publication Number Publication Date
EA201001781A1 true EA201001781A1 (ru) 2011-06-30
EA018333B1 EA018333B1 (ru) 2013-07-30

Family

ID=40757058

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001781A EA018333B1 (ru) 2008-05-13 2009-05-08 Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов

Country Status (7)

Country Link
US (1) US8735373B2 (ru)
EP (2) EP2296670B1 (ru)
EA (1) EA018333B1 (ru)
ES (1) ES2405314T3 (ru)
PL (1) PL2296670T3 (ru)
PT (1) PT2296670E (ru)
WO (1) WO2009138843A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241953B2 (en) 2008-05-13 2016-01-26 Apharm S.R.L. Glycosaminoglycan oral use and compositions
IT1402382B1 (it) * 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico
ES2444145T3 (es) 2011-11-24 2014-02-24 Quimera Ingeniería Biomédica, S.L. Complejo obtenido a partir de mezclas de ácido hialurónico o una sal del mismo y sulfato de condroitina
US20160243154A1 (en) * 2013-10-23 2016-08-25 Donald W. Jessup Hyaluronic acid formulation
CN108601796B (zh) * 2015-10-13 2020-03-03 技术防卫株式会社 胃肠道粘膜保护组合物
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
WO2018209008A1 (en) 2017-05-11 2018-11-15 Avicenna Nutracetical, Llc Methods for producing collagen
IT201700108526A1 (it) 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
IT201700124424A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
IT201800004332A1 (it) * 2018-04-09 2019-10-09 Composizione liquida per uso nel trattamento della mucosa del tratto oro-faringo-laringo-esofageo
IT202100021995A1 (it) * 2021-08-27 2023-02-27 Neilos S R L Composizione per la prevenzione e/o il trattamento delle patologie gastriche ed esofagee

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU555747B2 (en) 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
US20030232100A1 (en) 1998-04-08 2003-12-18 Theoharides Theoharis C. Compositions for treatment of diseases arising from secretion of mast cell biochemicals
ATE361082T1 (de) * 1999-02-01 2007-05-15 Dermal Res Lab Inc Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
GB9910212D0 (en) 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
CA2417867C (en) 2000-07-31 2012-09-11 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
ITMI20010611A1 (it) * 2001-03-22 2002-09-22 Ibsa Inst Biochimique Sa Cerotto idrocolloidale cicatrizzante contenete acido ialuronico e condroitin solfato
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
ITMI20012200A1 (it) 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
US7008626B2 (en) * 2001-11-05 2006-03-07 Seikagaku Corporation Medical composition for protuberance of epithelium
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
WO2003090763A1 (en) * 2002-04-24 2003-11-06 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
US7504387B2 (en) 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US8455458B2 (en) * 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage

Also Published As

Publication number Publication date
WO2009138843A9 (en) 2010-02-25
ES2405314T3 (es) 2013-05-30
EP2296670A1 (en) 2011-03-23
PL2296670T3 (pl) 2013-07-31
WO2009138843A1 (en) 2009-11-19
EA018333B1 (ru) 2013-07-30
EP2581090A1 (en) 2013-04-17
US20110071106A1 (en) 2011-03-24
US8735373B2 (en) 2014-05-27
EP2296670B1 (en) 2013-02-27
PT2296670E (pt) 2013-03-25

Similar Documents

Publication Publication Date Title
EA201001781A1 (ru) Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201200794A1 (ru) Триазолопиридины
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201270575A1 (ru) Соединения
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
EA201590835A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
NZ607580A (en) N-heteroaryl compounds
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
EA201490166A1 (ru) Фторированные арилалкиламинокарбоксамидные производные
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM